Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Summary of Significant Accounting Policies

Disaggregation Of Revenue

In thousands of US dollars ($)		Year Ended December 31, 2018
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	273	$	—	$	273
Concentrate Products
Product Sales – Point-in-time		60,995		52,264		8,731
License Fee – Point-in-time		2,121		2,121		—
Total Concentrate Products		63,116		54,385		8,731
Net Revenue	$	63,389	$	54,385	$	9,004
		Year Ended December 31, 2017
Products By Geographic Area		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	229		—		229
Concentrate Products
Product Sales – Point-in-time		54,972		48,307		6,665
License Fee – Point-in-time		2,099		2,099		—
Total Concentrate Products		57,071		50,406		6,665
Net Revenue	$	57,300	$	50,406	$	6,894

Contract Balances

In thousands of US dollars ($)	December 31, 2018		December 31, 2017
Receivables, which are included in "Trade and other receivables"	$	6,980	$	6,356
Contract liabilities	$	14,329	$	16,723

Summary of potentially dilutive securities

	As of December 31,
	2018		2017
Options to purchase common stock		8,244,605		6,906,001
Unvested restricted stock awards		146,800		480,000
Unvested restricted stock units		1,461,917		-
		9,853,322		7,386,001